Pharmaceuticals News and Research

RSS

Anthera continues Phase 2b PEARL-SC clinical study in SLE patients

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Roche selects ICON as technology partner

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Roche as its technology partner for storing and managing medical images collected during the company's clinical research programs.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

Simulations Plus second quarter revenues increase to record $2.789M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported preliminary revenues for its second quarter of fiscal year 2012 ended February 29, 2012 (2QFY12).

5 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).

5 Mar 2012

Lixiu, BIEL announce distribution agreement for RecoveryRx devices

BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. -- to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

Mylan comments on patent infringement ruling against Sunovion's Brovana

Mylan Inc. today commented on a ruling for partial summary judgment in its patent infringement lawsuit against Sunovion Pharmaceuticals Inc. in relation to Sunovion's Brovana product.

3 Mar 2012

New pharma code expands guidelines for interactions with health care providers

A new practice code for pharmaceutical companies now covers all interactions with health care professionals and bans them from giving payments to doctors to attend conferences.

3 Mar 2012

Roundup: Iowa lawmaker urges waiting on exchange bill until court rules; Calif. group finds way to recycle medicine

Democrats and Republicans disagree about whether the Legislature needs to approve a health insurance exchange this spring. At a Statehouse forum on the issue Thursday, state Sen. Brad Zaun noted that the U.S. Supreme Court is expected to rule this summer on whether major portions of the health reform law are constitutional. Zaun, an Urbandale Republican who opposes the overall law, said it makes sense to wait until after that decision before deciding whether to move ahead with the exchange.

3 Mar 2012

Viewpoints: The defeated Blunt Amendment, Obama's $100B Catholic hospital risk, fixing drug shortages

The amendment, which was attached to a highway bill, was defeated on a narrow 48-to-51 vote. But it showed once again how far from the mainstream Republicans have strayed in their relentless efforts to undermine the separation of church and state, deny women access to essential health services and tear apart President Obama's health care reform law.

3 Mar 2012

CLR01 blocks toxic aggregations of proteins in mouse model of Parkinson's

Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

2 Mar 2012

Watson introduces generic PROMETRIUM for endometrial hyperplasia

Watson Pharmaceuticals, Inc. today confirmed that Watson has launched an authorized generic version of PROMETRIUM (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories.

2 Mar 2012

First Edition: March 2, 2012

Today's headlines include reports about the Senate's vote to reject an effort to expand exemptions to the Obama administration's birth control coverage rule.

2 Mar 2012

Women need more contraception options that protect against pregnancy, HIV

In this Huffington Post "Black Voices" opinion piece, Vanessa Cullins, vice president for external medical affairs at Planned Parenthood Federation of America, responds to an announcement by the WHO in February that the agency would not revise its contraception guidelines for women living with and at risk of HIV infection based on a "study suggesting that hormonal contraception increases women's risk of acquiring and transmitting HIV to their partners."

2 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

New NPS information on dextropropoxyphene: recommendations and alternatives

NPS has published information online for prescribers to help them prepare for the TGA’s cancellation of Capadex and Paradex, two of the four medicines available in Australia containing dextropropoxyphene.

1 Mar 2012